Skip to main content
SpringerLink
Log in

Immunogenetics of Cancer

  • Chapter
  • First Online:
Cancer Immunology

  • 2101 Accesses

Abstract

The immune system, a system with an undeniable but complex role in malignancies significantly can influence the face of malignancy with respect to predisposition, nature, prognosis, and response to treatment in each individual. The immune system of each individual is subject to variability due to different environmental factors and most importantly due to an uncountable number of polymorphisms in genes governing the immune system elements and cells. Immunogenetics, as the meeting point of two exciting fields of immunology and genetics, is a new but rapidly expanding field of science studying this immune polymorphism in order to understand the governance of genetics on the immune system. In this chapter, we will review the importance of immunogenetics in human cancers, its ups and downs through the history, its tools, their major limitations and definition of immune polymorphisms. Finally, we will end this chapter by reviewing the impact of genetic polymorphisms of the two most important groups of immune-related genes (i.e., human leukocyte antigen and cytokines) which were under the focus of researchers in the fields of immunogenetics and cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wilson S, Jones L, Couseens C, et al. Cancer and the environment: gene-environment interaction. Washington, DC: National Academies Press (US); 2002.

    Google Scholar 

  2. Burgess DJ. Cancer genetics: initially complex, always heterogeneous. Nat Rev Cancer. 2011;11(3):153.

    Article  CAS  PubMed  Google Scholar 

  3. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061–73.

    Article  CAS  PubMed  Google Scholar 

  4. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: a SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. BioTechniques. 2002;(Suppl):48–50, 52, 54.

    Google Scholar 

  5. Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315(1):68–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fostira F, Thodi G, Konstantopoulou I, Sandaltzopoulos R, Yannoukakos D. Hereditary cancer syndromes. J BUON. 2007;12(Suppl 1):S13–22.

    PubMed  Google Scholar 

  7. Perez-Losada J, Castellanos-Martin A, Mao JH. Cancer evolution and individual susceptibility. Integr Biol. 2011;3(4):316–28.

    Article  CAS  Google Scholar 

  8. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.

    Article  CAS  PubMed  Google Scholar 

  9. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol. 2000;34(1):1–25.

    Article  CAS  PubMed  Google Scholar 

  10. Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Exp. 2010;58(6):435–48.

    Article  CAS  Google Scholar 

  11. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195(3):346–55.

    Article  CAS  PubMed  Google Scholar 

  12. Andor N, Maley CC, Ji HP. Genomic instability in cancer: teetering on the limit of tolerance. Cancer Res. 2017;77(9):2179–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother. 2011;60(8):1161–71.

    Article  CAS  PubMed  Google Scholar 

  14. Croci DO, Salatino M. Tumor immune escape mechanisms that operate during metastasis. Curr Pharm Biotechnol. 2011;12(11):1923–36.

    Article  CAS  PubMed  Google Scholar 

  15. Howell WM, Calder PC, Grimble RF. Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc. 2002;61(4):447–56.

    Article  CAS  PubMed  Google Scholar 

  16. Jin P, Wang E. Polymorphism in clinical immunology – from HLA typing to immunogenetic profiling. J Transl Med. 2003;1(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Simpson J, Roberts M. Modelling heterogeneous host immune response in a multi-strain system. J Theor Biol. 2012;304:60–5.

    Article  PubMed  Google Scholar 

  18. Strachan TR, Read AP. Human molecular genetics. 2nd ed. New York: Wiley-Liss; 1999.

    Google Scholar 

  19. Wills C. Rapid recent human evolution and the accumulation of balanced genetic polymorphisms. High Alt Med Biol. 2011;12(2):149–55.

    Article  PubMed  Google Scholar 

  20. Cobey S, Pascual M. Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition. J Theor Biol. 2011;270(1):80–7.

    Article  PubMed  Google Scholar 

  21. Wang E, Panelli MC, Monsurro V, Marincola FM. A global approach to tumor immunology. Cell Mol Immunol. 2004;1(4):256–65.

    CAS  PubMed  Google Scholar 

  22. Jin P, Panelli MC, Marincola FM, Wang E. Cytokine polymorphism and its possible impact on cancer. Immunol Res. 2004;30(2):181–90.

    Article  CAS  PubMed  Google Scholar 

  23. Ho DWH, Chan D, Cheung KMC, Sham P, Song Y-Q. (ii) Family-based linkage and case control association studies. Curr Orthop. 2008;22(4):245–50.

    Article  Google Scholar 

  24. Pampin S, Rodriguez-Rey JC. Functional analysis of regulatory single-nucleotide polymorphisms. Curr Opin Lipidol. 2007;18(2):194–8.

    Article  CAS  PubMed  Google Scholar 

  25. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009;20(1):43–59.

    Article  CAS  PubMed  Google Scholar 

  26. Cline MS, Karchin R. Using bioinformatics to predict the functional impact of SNVs. Bioinformatics. 2011;27(4):441–8.

    Article  CAS  PubMed  Google Scholar 

  27. Mooney S. Bioinformatics approaches and resources for single nucleotide polymorphism functional analysis. Brief Bioinform. 2005;6(1):44–56.

    Article  CAS  PubMed  Google Scholar 

  28. Yuzhalin A. The role of interleukin DNA polymorphisms in gastric cancer. Hum Immunol. 2011;72(11):1128–36.

    Article  CAS  PubMed  Google Scholar 

  29. Tariman JD, Dhorajiwala S. Genomic variants associated with cancer-related fatigue: a systematic review. Clin J Oncol Nurs. 2016;20(5):537–46.

    Article  PubMed  Google Scholar 

  30. Liu XS, Mardis ER. Applications of immunogenomics to cancer. Cell. 2017;168(4):600–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137(1 Suppl):194s–9s.

    Article  CAS  PubMed  Google Scholar 

  32. Cano P, Klitz W, Mack SJ, Maiers M, Marsh SG, Noreen H, et al. Common and well-documented HLA alleles: report of the ad-hoc committee of the American society for histocompatibility and immunogenetics. Hum Immunol. 2007;68(5):392–417.

    Article  CAS  PubMed  Google Scholar 

  33. Middleton D, Marsh SG. 16th International HLA and Immunogenetics Workshop (IHIW) introduction. Int J Immunogenet. 2013;40(1):1.

    CAS  PubMed  Google Scholar 

  34. Irwin MR, Cumley RW. Immunogenetic studies of species: qualitative differences in the serum of backcross progeny following a generic cross in birds. Genetics. 1942;27(2):228–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Discombe G. Blood Transfusion Accidents. Br Med J. 1953;2(4835):569.

    Google Scholar 

  36. Bontadini A. HLA techniques: typing and antibody detection in the laboratory of immunogenetics. Methods. 2012;56(4):471–6.

    Article  CAS  PubMed  Google Scholar 

  37. Bateman AC, Howell WM. Human leukocyte antigens and cancer: is it in our genes? J Pathol. 1999;188(3):231–6.

    Article  CAS  PubMed  Google Scholar 

  38. Hill AV. Immunogenetics and genomics. Lancet. 2001;357(9273):2037–41.

    Article  CAS  PubMed  Google Scholar 

  39. Weiling F. Historical study: Johann Gregor Mendel 1822–1884. Am J Med Genet. 1991;40(1):1–25.. discussion 6

    Article  CAS  PubMed  Google Scholar 

  40. Lederberg J. What the double helix (1953) has meant for basic biomedical science. A personal commentary. JAMA. 1993;269(15):1981–5.

    Article  CAS  PubMed  Google Scholar 

  41. Eaton L. Human genome project completed. BMJ. 2003;326(7394):838.

    Google Scholar 

  42. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.

    Article  CAS  PubMed  Google Scholar 

  43. International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789–96.

    Article  CAS  Google Scholar 

  44. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851–61.

    Article  CAS  PubMed  Google Scholar 

  45. Boomsma D, Busjahn A, Peltonen L. Classical twin studies and beyond. Nat Rev Genet. 2002;3(11):872–82.

    Article  CAS  PubMed  Google Scholar 

  46. Mocellin S, Wang E, Panelli M, Pilati P, Marincola FM. DNA array-based gene profiling in tumor immunology. Clin Cancer Res. 2004;10(14):4597–606.

    Article  CAS  PubMed  Google Scholar 

  47. Nowotny P, Kwon JM, Goate AM. SNP analysis to dissect human traits. Curr Opin Neurobiol. 2001;11(5):637–41.

    Article  CAS  PubMed  Google Scholar 

  48. Cerhan JR. Host genetics in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):121–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Morton NE, Collins A. Toward positional cloning with SNPs. Curr Opin Mol Ther. 2002;4(3):259–64.

    CAS  PubMed  Google Scholar 

  50. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature. 2003;422(6934):835–47.

    Article  CAS  PubMed  Google Scholar 

  51. Ke X, Taylor MS, Cardon LR. Singleton SNPs in the human genome and implications for genome-wide association studies. Eur J Hum Genet. 2008;16(4):506–15.

    Article  CAS  PubMed  Google Scholar 

  52. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23):9362–7.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Palmer LJ, Cardon LR. Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet. 2005;366(9492):1223–34.

    Article  CAS  PubMed  Google Scholar 

  54. Gogele M, Minelli C, Thakkinstian A, Yurkiewich A, Pattaro C, Pramstaller PP, et al. Methods for meta-analyses of genome-wide association studies: critical assessment of empirical evidence. Am J Epidemiol. 2012;175(8):739–49.

    Article  PubMed  Google Scholar 

  55. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363(2):166–76.

    Article  CAS  PubMed  Google Scholar 

  56. Brower V. AIDS-related cancers increase in Africa. J Natl Cancer Inst. 2011;103(12):918–9.

    Article  PubMed  Google Scholar 

  57. Tanon A, Jaquet A, Ekouevi DK, Akakpo J, Adoubi I, Diomande I, et al. The spectrum of cancers in West Africa: associations with human immunodeficiency virus. PLoS One. 2012;7(10):e48108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Taioli E. Gene-environment interaction in tobacco-related cancers. Carcinogenesis. 2008;29(8):1467–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004;14(6):473–86.

    Article  CAS  PubMed  Google Scholar 

  60. Lander ES, Schork NJ. Genetic dissection of complex traits. Science (New York, NY). 1994;265(5181):2037–48.

    Article  CAS  Google Scholar 

  61. Madeleine MM, Johnson LG, Smith AG, Hansen JA, Nisperos BB, Li S, et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 2008;68(9):3532–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk--a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1920–8.

    Article  CAS  PubMed  Google Scholar 

  63. Wang J, Pan HF, Hu YT, Zhu Y, He Q. Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: a meta-analysis. Dig Dis Sci. 2010;55(7):1818–23.

    Article  CAS  PubMed  Google Scholar 

  64. Qiu LX, Yao L, Mao C, Chen B, Zhan P, Xue K, et al. TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects. Breast Cancer Res Treat. 2010;123(2):563–7.

    Article  CAS  PubMed  Google Scholar 

  65. Liu F, Li B, Wei YG, Chen X, Ma Y, Yan LN, et al. IFN-gamma+874 A/T polymorphism and cancer risk: an updated analysis based on 32 case-control studies. Cytokine. 2011;56(2):200–7.

    Article  CAS  PubMed  Google Scholar 

  66. Wang J, Ding Q, Shi Y, Cao Q, Qin C, Zhu J, et al. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis. 2012;27(3):305–12.

    Article  CAS  PubMed  Google Scholar 

  67. Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, et al. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol. 2011;17(34):3941–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Balmain A, Harris CC. Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis. 2000;21(3):371–7.

    Article  CAS  PubMed  Google Scholar 

  69. Hunter KW, Crawford NP. The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. Annu Rev Genet. 2008;42:131–41.

    Article  CAS  PubMed  Google Scholar 

  70. Darvasi A. ‘Dissecting complex traits: the geneticists’ “Around the world in 80 days”. Trends Genet. 2005;21(7):373–6.

    Article  CAS  PubMed  Google Scholar 

  71. Chen F, Xu Z, Lu J, Lu X, Mu WL, Wang YJ, et al. Gaussia luciferase reporter assay for assessment of gene delivery systems in vivo. Chin Med Sci J. 2010;25(2):95–9.

    Article  CAS  PubMed  Google Scholar 

  72. Uchiyama T, Miyazaki K. Product-induced gene expression, a product-responsive reporter assay used to screen metagenomic libraries for enzyme-encoding genes. Appl Environ Microbiol. 2010;76(21):7029–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Yaginuma K, Koike K. Technics in molecular biology for cancer research--electrophoretic mobility-shift assay. Gan To Kagaku Ryoho [Cancer Chemother]. 1989;16(3 Pt 1):435–41.

    CAS  Google Scholar 

  74. Kirigiti P, Machida CA. Electrophoretic mobility shift assay for detection of DNA binding proteins recognizing beta-adrenergic receptor gene sequences. Methods Mol Biol. 2000;126:431–51.

    CAS  PubMed  Google Scholar 

  75. Li K, Xia F, Zhang K, Mo A, Liu L. Association of a tgf-b1-509c/t polymorphism with gastric cancer risk: a meta-analysis. Ann Hum Genet. 2013;77(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  76. Wu Y, Liu B, Lin W, Xu Y, Li L, Zhang Y, et al. Human leukocyte antigen class II alleles and risk of cervical cancer in China. Hum Immunol. 2007;68(3):192–200.

    Article  CAS  PubMed  Google Scholar 

  77. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, et al. Correlation of HLA-A02∗ genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother. 2012;61(8):1243–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Madeleine MM, Brumback B, Cushing-Haugen KL, Schwartz SM, Daling JR, Smith AG, et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis. 2002;186(11):1565–74.

    Article  CAS  PubMed  Google Scholar 

  79. Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, et al. Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin’s lymphoma. Genes Chromosomes Cancer. 2007;46(5):500–7.

    Article  CAS  PubMed  Google Scholar 

  80. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda). 2004;19:216–24.

    CAS  Google Scholar 

  81. Martin MP, Carrington M. Immunogenetics of HIV disease. Immunol Rev. 2013;254(1):245–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Oguz FS, Kalayoglu S, Diler AS, Tozkir H, Sargin D, Carin M, et al. HLA system affects the age-at-onset in chronic myeloid leukemia. Am J Hematol. 2003;73(4):256–62.

    Article  CAS  PubMed  Google Scholar 

  83. Diepstra A, Niens M, Vellenga E, van Imhoff GW, Nolte IM, Schaapveld M, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin’s lymphoma. Lancet. 2005;365(9478):2216–24.

    Article  CAS  PubMed  Google Scholar 

  84. Rhodes DA, Trowsdale J. Genetics and molecular genetics of the MHC. Rev Immunogenet. 1999;1(1):21–31.

    CAS  PubMed  Google Scholar 

  85. Noguchi K, Isogai M, Kuwada E, Noguchi A, Goto S, Egawa K. Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res. 2004;24(5c):3387–92.

    CAS  PubMed  Google Scholar 

  86. Powell AG, Horgan PG, Edwards J. The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key? J Cancer Res Clin Oncol. 2012;138(5):723–8.

    Article  CAS  PubMed  Google Scholar 

  87. Hassen E, Nahla G, Bouaouina N, Chouchane L. The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk. Mol Biol Rep. 2010;37(1):119–26.

    Article  CAS  PubMed  Google Scholar 

  88. Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, Beziat V, et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci Immunol. 2016;1(3):eaag1672.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Iwaszko M, Bogunia-Kubik K. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp. 2011;59(5):353–67.

    Article  CAS  Google Scholar 

  90. Ishitani A, Sageshima N, Hatake K. The involvement of HLA-E and -F in pregnancy. J Reprod Immunol. 2006;69(2):101–13.

    Article  CAS  PubMed  Google Scholar 

  91. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science (New York, NY). 1990;248(4952):220–3.

    Article  CAS  Google Scholar 

  92. Blaschitz A, Lenfant F, Mallet V, Hartmann M, Bensussan A, Geraghty DE, et al. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol. 1997;27(12):3380–8.

    Article  CAS  PubMed  Google Scholar 

  93. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol. 2000;48(1):17–26.

    Article  CAS  PubMed  Google Scholar 

  94. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20(3):375–83.

    Article  CAS  PubMed  Google Scholar 

  95. Gooden MJ, van Hall T. Infiltrating CTLs are bothered by HLA-E on tumors. Oncoimmunology. 2012;1(1):92–3.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Robinson J, Halliwell JA, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res. 2013;41(Database issue):D1222–7.

    CAS  PubMed  Google Scholar 

  97. Niens M, van den Berg A, Diepstra A, Nolte IM, van der Steege G, Gallagher A, et al. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin’s lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2280–4.

    Article  CAS  PubMed  Google Scholar 

  98. Bochtler W, Maiers M, Bakker JN, Baier DM, Hofmann JA, Pingel J, et al. An update to the HLA Nomenclature Guidelines of the World Marrow Donor Association, 2012. Bone Marrow Transplant. 2013;48(11):1387–8.

    Article  CAS  PubMed  Google Scholar 

  99. Gires O, Seliger B, editors. Tumor-associated antigens: identification, characterization, and clinical applications. Weinheim: Wiley-Blackwell; 2009.

    Google Scholar 

  100. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(8):2067–75.

    Article  CAS  Google Scholar 

  101. Maat W, Haasnoot GW, Claas FH, Schalij-Delfos NE, Schreuder GM, Jager MJ. HLA class I and II genotype in uveal melanoma: relation to occurrence and prognosis. Invest Ophthalmol Vis Sci. 2006;47(1):3–6.

    Article  PubMed  Google Scholar 

  102. Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X, et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood. 2010;115(23):4820–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Sidney J, del Guercio MF, Southwood S, Hermanson G, Maewal A, Appella E, et al. The HLA-A∗0207 peptide binding repertoire is limited to a subset of the A∗0201 repertoire. Hum Immunol. 1997;58(1):12–20.

    Article  CAS  PubMed  Google Scholar 

  104. Huang X, Hepkema B, Nolte I, Kushekhar K, Jongsma T, Veenstra R, et al. HLA-A∗02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLoS One. 2012;7(2):e31865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, et al. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol. 2006;103(1):145–50.

    Article  CAS  PubMed  Google Scholar 

  106. Bahls L, Yamakawa R, Zanao K, Alfieri D, Flauzino T, Delongui F, et al. Human leukocyte antigen class I and class II polymorphisms and serum cytokine profiles in cervical cancer. Int J Mol Sci. 2017;18(9):pii: E1478.

    Article  CAS  Google Scholar 

  107. Shugart YY, Wang Y, Jia WH, Zeng YX. GWAS signals across the HLA regions: revealing a clue for common etiology underlying infectious tumors and other immunity diseases. Chin J Cancer. 2011;30(4):226–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. De Re V, Caggiari L, Talamini R, Crovatto M, De Vita S, Mazzaro C, et al. Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. Hum Immunol. 2004;65(11):1397–404.

    Article  CAS  PubMed  Google Scholar 

  109. Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, et al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science (New York, NY). 2018;359(6371):86–90.

    Article  CAS  Google Scholar 

  110. Litwin TR, Clarke MA, Dean M, Wentzensen N. Somatic host cell alterations in HPV carcinogenesis. Viruses. 2017;9(8):pii: E206.

    Article  CAS  Google Scholar 

  111. Rodriguez JA. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncol Lett. 2017;14(4):4415–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Tang M, Lautenberger JA, Gao X, Sezgin E, Hendrickson SL, Troyer JL, et al. The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. PLoS Genet. 2012;8(11):e1003103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, et al. Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer. 2001;32(1):39–46.

    Article  CAS  PubMed  Google Scholar 

  114. Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today. 1998;19(12):539–42.

    Article  CAS  PubMed  Google Scholar 

  115. Li X, Fasano R, Wang E, Yao KT, Marincola FM. HLA associations with nasopharyngeal carcinoma. Curr Mol Med. 2009;9(6):751–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–71.e11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Akers NK, Curry JD, Conde L, Bracci PM, Smith MT, Skibola CF. Association of HLA-DQB1 alleles with risk of follicular lymphoma. Leuk Lymphoma. 2011;52(1):53–8.

    Article  CAS  PubMed  Google Scholar 

  118. van der Woude D, Lie BA, Lundstrom E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1∗1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 2010;62(5):1236–45.

    Google Scholar 

  119. Wang SS, Lu Y, Rothman N, Abdou AM, Cerhan JR, De Roos A, et al. Variation in effects of non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1∗01:01 allele and ancestral haplotype 8.1. PLoS One. 2011;6(11):e26949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res. 1992;52(23):6561–6.

    CAS  PubMed  Google Scholar 

  121. Wan R, Wang ZW, Li H, Peng XD, Liu GY, Ou JM, et al. Human leukocyte antigen-G inhibits the anti-tumor effect of natural killer cells via immunoglobulin-like transcript 2 in gastric cancer. Cell Physiol Biochem. 2017;44(5):1828–41.

    Article  CAS  PubMed  Google Scholar 

  122. De Re V, Caggiari L, Mussolin L, d’Amore ES, Famengo B, De Zorzi M, et al. HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin’s lymphoma. Oncotarget. 2017;8(62):105957–70.

    PubMed  PubMed Central  Google Scholar 

  123. Garziera M, Scarabel L, Toffoli G. Hypoxic modulation of HLA-G expression through the metabolic sensor HIF-1 in human cancer cells. J Immunol Res. 2017;2017:4587520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Dausset J. Iso-leuko-antibodies. Acta Haematol. 1958;20(1–4):156–66.

    Article  CAS  PubMed  Google Scholar 

  125. Mittal KK, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation. 1968;6(8):913–27.

    Article  CAS  PubMed  Google Scholar 

  126. Uryu N, Maeda M, Ota M, Tsuji K, Inoko H. A simple and rapid method for HLA-DRB and -DQB typing by digestion of PCR-amplified DNA with allele specific restriction endonucleases. Tissue Antigens. 1990;35(1):20–31.

    Article  CAS  PubMed  Google Scholar 

  127. Krausa P, Browning MJ. A comprehensive PCR-SSP typing system for identification of HLA-A locus alleles. Tissue Antigens. 1996;47(3):237–44.

    Article  CAS  PubMed  Google Scholar 

  128. Donaldson PT, Ho S, Williams R, Johnson PJ. HLA class II alleles in Chinese patients with hepatocellular carcinoma. Liver. 2001;21(2):143–8.

    Article  CAS  PubMed  Google Scholar 

  129. Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, et al. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer. 1997;75(2):283–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Xin YN, Lin ZH, Jiang XJ, Zhan SH, Dong QJ, Wang Q, et al. Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2011;17(17):2248–54.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Zhang X, Lv Z, Yu H, Wang F, Zhu J. The HLA-DQB1 gene polymorphisms associated with cervical cancer risk: a meta-analysis. Biomed Pharmacother. 2015;73:58–64.

    Article  CAS  PubMed  Google Scholar 

  132. Liu L, Guo W, Zhang J. Association of HLA-DRB1 gene polymorphisms with hepatocellular carcinoma risk: a meta-analysis. Minerva Med. 2017;108(2):176–84.

    PubMed  Google Scholar 

  133. Yao K, Yang S, Shen J, Zhang R, Li L. HLA-DRB1 allele polymorphism and nasopharyngeal carcinoma risk: a meta-analysis. Eur Arch Otorhinolaryngol. 2017;274(1):297–303.

    Article  PubMed  Google Scholar 

  134. Wei LZ, Wang HL, Liu X, Lu YP, Xu F, Yuan JQ, et al. Meta-analysis on the relationship between HLA-DRBl gene polymorphism and cervical cancer in Chinese population. PLoS One. 2014;9(2):e88439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis. BMC Gastroenterol. 2010;10:145.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Yang YC, Chang TY, Lee YJ, Su TH, Dang CW, Wu CC, et al. HLA-DRB1 alleles and cervical squamous cell carcinoma: experimental study and meta-analysis. Hum Immunol. 2006;67(4–5):331–40.

    Article  CAS  PubMed  Google Scholar 

  137. Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ. HLA and nasopharyngeal carcinoma in Chinese--a further study. Int J Cancer. 1983;32(2):171–6.

    Article  CAS  PubMed  Google Scholar 

  138. Simons MJ, Wee GB, Goh EH, Chan SH, Shanmugaratnam K, Day NE, et al. Immunogenetic aspects of nasopharyngeal carcinoma. IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2). J Natl Cancer Inst. 1976;57(5):977–80.

    Article  CAS  PubMed  Google Scholar 

  139. Burt RD, Vaughan TL, Nisperos B, Swanson M, Berwick M. A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians. Int J Cancer. 1994;56(4):465–7.

    Article  CAS  PubMed  Google Scholar 

  140. Pasini E, Caggiari L, Dal Maso L, Martorelli D, Guidoboni M, Vaccher E, et al. Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. Int J Cancer. 2009;125(6):1358–64.

    Article  CAS  PubMed  Google Scholar 

  141. Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, Smith AG, et al. Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol Biomarkers Prev. 1996;5(11):879–87.

    CAS  PubMed  Google Scholar 

  142. Krausa P, Brywka M 3rd, Savage D, Hui KM, Bunce M, Ngai JL, et al. Genetic polymorphism within HLA-A∗02: significant allelic variation revealed in different populations. Tissue Antigens. 1995;45(4):223–31.

    Article  CAS  PubMed  Google Scholar 

  143. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002;94(23):1780–9.

    Article  CAS  PubMed  Google Scholar 

  144. Chan PK, Cheung TH, Lin CK, Siu SS, Yim SF, Lo KW, et al. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese. J Med Virol. 2007;79(7):970–6.

    Article  PubMed  Google Scholar 

  145. Maciag PC, Schlecht NF, Souza PS, Franco EL, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1183–91.

    CAS  PubMed  Google Scholar 

  146. Torgerson SR, Haddad RY, Atallah E. Chronic myelogenous leukemia for primary care physicians. Dis Mon. 2012;58(4):168–76.

    Article  PubMed  Google Scholar 

  147. Yan WH. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets. 2011;11(1):76–89.

    Google Scholar 

  148. Zhang Y, Yu S, Han Y, Wang Y, Sun Y. Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment. Oncol Lett. 2018;15(1):699–709.

    PubMed  Google Scholar 

  149. Zeng XC, Zhang T, Huang DH, Wang GY, Chen W, Li H, et al. RNA interfering targeting human leukocyte antigen-G enhanced immune surveillance mediated by the natural killer cells on hepatocellular carcinoma. Ann Clin Lab Sci. 2013;43(2):135–44.

    CAS  PubMed  Google Scholar 

  150. Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011;117(26):7021–31.

    Article  CAS  PubMed  Google Scholar 

  151. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (New York, NY). 2018;359(6375):582–7.

    Article  CAS  Google Scholar 

  152. Muller M, Gfeller D, Coukos G, Bassani-Sternberg M. ‘Hotspots’ of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front Immunol. 2017;8:1367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Liu Z, Zhao Y, Fang J, Cui R, Xiao Y, Xu Q. SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget. 2017;8(32):53518–30.

    PubMed  PubMed Central  Google Scholar 

  154. Ahirwar DK, Manchanda PK, Mittal RD, Bid HK. BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol. 2011;137(12):1729–38.

    Article  CAS  PubMed  Google Scholar 

  155. Wang N, Zhou R, Wang C, Guo X, Chen Z, Yang S, et al. 251 T/A polymorphism of the interleukin-8 gene and cancer risk: a HuGE review and meta-analysis based on 42 case-control studies. Mol Biol Rep. 2012;39(3):2831–41.

    Article  CAS  PubMed  Google Scholar 

  156. Xu J, Yin Z, Cao S, Gao W, Liu L, Yin Y, et al. Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One. 2013;8(5):e63654.

    Article  PubMed  PubMed Central  Google Scholar 

  157. Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B. Cytokine gene polymorphisms can alter the effect of bacillus Calmette-Guerin (BCG) immunotherapy. Cytokine. 2006;35(1–2):1–5.

    Article  CAS  PubMed  Google Scholar 

  158. Yu KD, Di GH, Fan L, Chen AX, Yang C, Shao ZM. Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Treat. 2010;122(2):483–8.

    Article  CAS  PubMed  Google Scholar 

  159. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol. 2003;171(12):6448–56.

    Article  CAS  PubMed  Google Scholar 

  160. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25(3):387–408.

    Article  CAS  PubMed  Google Scholar 

  161. SNP FAQ Archive [Internet]. Bethesda: National Center for Biotechnology Information (US); 2005. Available from: http://www.ncbi.nlm.nih.gov/books/NBK3848/.

  162. Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annotation, interpretation and analysis. Nucleic Acids Res. 2012;40(Database issue):D1308–12.

    Article  CAS  PubMed  Google Scholar 

  163. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124(5):1193–201.

    Article  CAS  PubMed  Google Scholar 

  164. Al-Moundhri MS, Alkindy M, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Habsi H, et al. Combined polymorphism analysis of glutathione S-transferase M1/G1 and interleukin-1B (IL-1B)/interleukin 1-receptor antagonist (IL-1RN) and gastric cancer risk in an Omani Arab population. J Clin Gastroenterol. 2009;43(2):152–6.

    Article  CAS  PubMed  Google Scholar 

  165. Kupcinskas L, Wex T, Kupcinskas J, Leja M, Ivanauskas A, Jonaitis LV, et al. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms are not associated with premalignant gastric conditions: a combined haplotype analysis. Eur J Gastroenterol Hepatol. 2010;22(10):1189–95.

    Article  CAS  PubMed  Google Scholar 

  166. Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, et al. Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis. Oncol Rep. 2008;20(5):1213–20.

    PubMed  Google Scholar 

  167. Chen B, Luo MX, Zhou X, Lv Y, Su GQ. Correlation between Interleukin-1beta-511 C/T polymorphism and gastric cancer in Chinese populations: a meta-analysis. Med Sci Monit. 2016;22:1742–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Park MJ, Hyun MH, Yang JP, Yoon JM, Park S. Effects of the interleukin-1beta-511 C/T gene polymorphism on the risk of gastric cancer in the context of the relationship between race and H. pylori infection: a meta-analysis of 20,000 subjects. Mol Biol Rep. 2015;42(1):119–34.

    Article  CAS  PubMed  Google Scholar 

  169. Wu S, Hu G, Chen J, Xie G. Interleukin 1beta and interleukin 1 receptor antagonist gene polymorphisms and cervical cancer: a meta-analysis. Int J Gynecol Cancer. 2014;24(6):984–90.

    Article  PubMed  Google Scholar 

  170. Lee YH, Song GG. A meta-analysis of the association between CTLA-4 +49 A/G, −318 C/T, and IL-1 polymorphisms and susceptibility to cervical cancer. Neoplasma. 2014;61(4):481–90.

    Article  CAS  PubMed  Google Scholar 

  171. Xu H, Ding Q, Jiang HW. Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk. Asian Pac J Cancer Prev. 2014;15(20):8741–7.

    Article  PubMed  Google Scholar 

  172. Li C, Wang C. Current evidences on IL1B polymorphisms and lung cancer susceptibility: a meta-analysis. Tumour Biol. 2013;34(6):3477–82.

    Article  CAS  PubMed  Google Scholar 

  173. Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39(5):5187–94.

    Article  CAS  PubMed  Google Scholar 

  174. Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol. 2011;137(7):1095–104.

    Article  PubMed  Google Scholar 

  175. Zhang Y, Liu C, Peng H, Zhang J, Feng Q. IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis. PLoS One. 2012;7(9):e46017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol. 2010;25(10):1604–17.

    Article  PubMed  Google Scholar 

  177. Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1674–87.

    Article  CAS  PubMed  Google Scholar 

  178. Loh M, Koh KX, Yeo BH, Song CM, Chia KS, Zhu F, et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 2009;45(14):2562–8.

    Article  CAS  PubMed  Google Scholar 

  179. Ying HY, Yu BW, Yang Z, Yang SS, Bo LH, Shan XY, et al. Interleukin-1B 31 C>T polymorphism combined with Helicobacter pylori-modified gastric cancer susceptibility: evidence from 37 studies. J Cell Mol Med. 2016;20(3):526–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(6):947–52.

    Article  CAS  PubMed  Google Scholar 

  181. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis. 2002;34(2):204–9.

    Article  CAS  PubMed  Google Scholar 

  182. Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, et al. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J Gastroenterol Hepatol. 2007;22(5):729–37.

    Article  CAS  PubMed  Google Scholar 

  183. Glas J, Torok HP, Schneider A, Brunnler G, Kopp R, Albert ED, et al. Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(23):4746–52.

    Article  CAS  Google Scholar 

  184. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer. 2005;92(5):921–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Nagai S, Toi M. Interleukin-4 and breast cancer. Breast Cancer. 2000;7(3):181–6.

    Article  CAS  PubMed  Google Scholar 

  186. Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J Gastroenterol. 2010;16(10):1188–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Zhang J, Xie D, Zhou H, Fan R, Zhang L, Li C, et al. The -590C/T polymorphism in the IL-4 gene and the risk of cancer: a meta-analysis. Tumour Biol. 2013;34(4):2261–8.

    Article  CAS  PubMed  Google Scholar 

  188. Li Q, Wang Q, Xu X, Ren S, Wang L. Association between IL-4 -589C>T polymorphism and colorectal cancer risk. Tumour Biol. 2014;35(3):2675–9.

    Article  CAS  PubMed  Google Scholar 

  189. Chen P, Chen C, Chen K, Xu T, Luo C. Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis. Tumour Biol. 2015;36(1):121–7.

    Article  CAS  PubMed  Google Scholar 

  190. Zhenzhen L, Xianghua L, Qingwei W, Zhan G, Ning S. Three common polymorphisms in the IL-4 gene and cancer risk: a meta-analysis involving 5,392 cases and 6,930 controls. Tumour Biol. 2013;34(4):2215–24.

    Article  CAS  PubMed  Google Scholar 

  191. Sun Z, Cui Y, Jin X, Pei J. Association between IL-4 -590C>T polymorphism and gastric cancer risk. Tumour Biol. 2014;35(2):1517–21.

    Article  CAS  PubMed  Google Scholar 

  192. Cho YA, Kim J. Association of IL4, IL13, and IL4R polymorphisms with gastrointestinal cancer risk: a meta-analysis. J Epidemiol. 2017;27(5):215–20.

    Article  PubMed  PubMed Central  Google Scholar 

  193. Jia Y, Xie X, Shi X, Li S. Associations of common IL-4 gene polymorphisms with cancer risk: a meta-analysis. Mol Med Rep. 2017;16(2):1927–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Waldner MJ, Foersch S, Neurath MF. Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Pantsulaia I, Trofimov S, Kobyliansky E, Livshits G. Genetic and environmental influences on IL-6 and TNF-alpha plasma levels in apparently healthy general population. Cytokine. 2002;19(3):138–46.

    Article  CAS  PubMed  Google Scholar 

  196. Smith AJ, D’Aiuto F, Palmen J, Cooper JA, Samuel J, Thompson S, et al. Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem. 2008;54(5):841–50.

    Article  CAS  PubMed  Google Scholar 

  197. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21(9):1458–63.

    Article  CAS  PubMed  Google Scholar 

  198. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, et al. Relationship between interleukin 6 promoter polymorphism at position −174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol. 2006;33(4):703–8.

    CAS  PubMed  Google Scholar 

  199. Ravaglia G, Forti P, Maioli F, Chiappelli M, Dolzani P, Martelli M, et al. Associations of the −174 G/C interleukin-6 gene promoter polymorphism with serum interleukin 6 and mortality in the elderly. Biogerontology. 2005;6(6):415–23.

    Article  CAS  PubMed  Google Scholar 

  200. Malarstig A, Wallentin L, Siegbahn A. Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome. Thromb Res. 2007;119(4):467–73.

    Article  CAS  PubMed  Google Scholar 

  201. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Ziakas PD, Karsaliakos P, Prodromou ML, Mylonakis E. Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies. Biomarkers. 2013;18(7):625–31.

    Article  CAS  PubMed  Google Scholar 

  203. Joshi N, Kannan S, Kotian N, Bhat S, Kale M, Hake S. Interleukin 6 -174G>C polymorphism and cancer risk: meta-analysis reveals a site dependent differential influence in ancestral north Indians. Hum Immunol. 2014;75(8):901–8.

    Article  CAS  PubMed  Google Scholar 

  204. Yu Y, Wang W, Zhai S, Dang S, Sun M. IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Mol Biol Rep. 2012;39(8):8457–63.

    Article  CAS  PubMed  Google Scholar 

  205. Hu JJ, Wang ZT, Zhong J. Lack of association between the interleukin 6 gene −174G>C polymorphism and colorectal cancer: evidence from a meta-analysis. Genet Mol Res. 2013;12(3):2205–14.

    Article  CAS  PubMed  Google Scholar 

  206. Wu M, Cao Y, Liu YL, Ma LL, Yang XH. Meta-analysis of the correlation between interleukin-6 promoter polymorphism -174G/C and Interferon Regulatory Factor 4 rs12203592 polymorphism with skin cancer susceptibility. Am J Ther. 2016;23(6):e1758–e67.

    Article  PubMed  Google Scholar 

  207. Wang S, Zhang W. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC. Tumour Biol. 2016;37(5):6561–9.

    Article  CAS  PubMed  Google Scholar 

  208. Tian G, Mi J, Wei X, Zhao D, Qiao L, Yang C, et al. Circulating interleukin-6 and cancer: a meta-analysis using Mendelian randomization. Sci Rep. 2015;5:11394.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Liu Y, Gao SJ, Du BX, Wang JJ. Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis. Tumour Biol. 2014;35(4):3551–61.

    Article  CAS  PubMed  Google Scholar 

  210. Yin YW, Sun QQ, Hu AM, Wang Q, Liu HL, Hou ZZ, et al. Associations between interleukin-6 gene -174 C/G and −572 C/G polymorphisms and the risk of gastric cancer: a meta-analysis. J Surg Oncol. 2012;106(8):987–93.

    Article  CAS  PubMed  Google Scholar 

  211. Wang J, He W, Liu J, Nong L, Wei Y, Yang F. Association of IL-6 polymorphisms with gastric cancer risk: evidences from a meta-analysis. Cytokine. 2012;59(1):176–83.

    Article  CAS  PubMed  Google Scholar 

  212. Liu Y, Song XL, Zhang GL, Peng AM, Fu PF, Li P, et al. Lack of association between IL-6 -174G>C polymorphism and lung cancer: a meta-analysis. Genet Mol Res. 2015;14(1):163–9.

    Article  CAS  PubMed  Google Scholar 

  213. Wang W, Chen J, Zhao F, Zhang B, Yu H. Lack of association between a functional polymorphism (rs1800796) in the interleukin-6 gene promoter and lung cancer. Diagn Pathol. 2014;9:134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Zhao Q, Zhang B, Chen Y, Li M, Zhao X, Fan H, et al. Association of the interleukin-6 gene -572G/C polymorphism with cancer risk: a meta-analysis. Genet Mol Res. 2015;14(4):16921–8.

    Article  CAS  PubMed  Google Scholar 

  215. Du Y, Gao L, Zhang K, Wang J. Association of the IL6 polymorphism rs1800796 with cancer risk: a meta-analysis. Genet Mol Res. 2015;14(4):13236–46.

    Google Scholar 

  216. Magalhaes JF, Cortinhas AJ, Albuquerque CM, Baptista CS, Ribeiro R, Viegas C, et al. Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk. Mol Biol Rep. 2013;40(1):449–55.

    Article  CAS  PubMed  Google Scholar 

  217. Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ, et al. The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res. 2005;11(18):6431–41.

    Article  CAS  PubMed  Google Scholar 

  218. Ahirwar DK, Mandhani A, Mittal RD. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort. Arch Med Res. 2010;41(2):97–103.

    Article  CAS  PubMed  Google Scholar 

  219. Gao LB, Pan XM, Jia J, Liang WB, Rao L, Xue H, et al. IL-8 -251A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. Eur J Cancer. 2010;46(8):1333–43.

    Article  CAS  PubMed  Google Scholar 

  220. Wang Z, Liu Y, Yang L, Yin S, Zang R, Yang G. The polymorphism interleukin-8 -251A/T is associated with a significantly increased risk of cancers from a meta-analysis. Tumour Biol. 2014;35(7):7115–23.

    Article  CAS  PubMed  Google Scholar 

  221. Wang Z, Wang C, Zhao Z, Liu F, Guan X, Lin X, et al. Association between -251A>T polymorphism in the interleukin-8 gene and oral cancer risk: a meta-analysis. Gene. 2013;522(2):168–76.

    Article  CAS  PubMed  Google Scholar 

  222. Huang Q, Wang C, Qiu LJ, Shao F, Yu JH. IL-8-251A>T polymorphism is associated with breast cancer risk: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(7):1147–50.

    Article  CAS  PubMed  Google Scholar 

  223. Gao P, Zhao H, You J, Jing F, Hu Y. Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis. Cancer Investig. 2014;32(10):518–25.

    Article  CAS  Google Scholar 

  224. Wang XB, Li YS, Li J, Han Y, Liu ZD. Interleukin-8 -251A/T gene polymorphism and lung cancer susceptibility: a meta-analysis. J Cell Mol Med. 2015;19(6):1218–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Xue H, Liu J, Lin B, Wang Z, Sun J, Huang G. A meta-analysis of interleukin-8 -251 promoter polymorphism associated with gastric cancer risk. PLoS One. 2012;7(1):e28083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  226. Yang L, Zhu X, Liang X, Ling Z, Li R. Association of IL-8-251A>T polymorphisms with oral cancer risk: evidences from a meta-analysis. Tumour Biol. 2014;35(9):9211–8.

    Article  CAS  PubMed  Google Scholar 

  227. Hu LX, Du YY, Zhang Y, Pan YY. Lack of association between interleukin-8-251 T>A polymorphism and colorectal cancer risk: a meta-analysis based on 3,019 cases and 3,984 controls. Asian Pac J Cancer Prev. 2012;13(10):5075–9.

    Article  PubMed  Google Scholar 

  228. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129.

    CAS  PubMed  PubMed Central  Google Scholar 

  229. Pan F, Tian J, Pan YY, Zhang Y. Association of IL-10-1082 promoter polymorphism with susceptibility to gastric cancer: evidence from 22 case-control studies. Mol Biol Rep. 2012;39(6):7143–54.

    Article  CAS  PubMed  Google Scholar 

  230. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349(9046):170–3.

    Article  CAS  PubMed  Google Scholar 

  231. Zou YF, Wang F, Feng XL, Tian YH, Tao JH, Pan FM, et al. Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects. Eur J Cancer. 2011;47(7):1072–9.

    Article  CAS  PubMed  Google Scholar 

  232. Ding Q, Shi Y, Fan B, Fan Z, Ding L, Li F, et al. The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls. PLoS One. 2013;8(2):e57246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Ni J, Ye Y, Teng F, Interleukin WQ. 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2013;23(1):126–33.

    Article  PubMed  Google Scholar 

  234. Cao HY, Zou P, Zhou H. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene. 2013;519(2):288–94.

    Article  CAS  PubMed  Google Scholar 

  235. Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer. 2012;12:102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  236. Cui X, Huang Q, Li X, Liu F, Wang D, Yan D, et al. Relationship between Interleukin-10 gene C-819T polymorphism and gastric cancer risk: insights from a meta-analysis. Med Sci Monit. 2016;22:2839–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  237. Niu YM, Du XY, Cai HX, Zhang C, Yuan RX, Zeng XT, et al. Increased risks between Interleukin-10 gene polymorphisms and haplotype and head and neck cancer: a meta-analysis. Sci Rep. 2015;5:17149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  238. Ni P, Xu H, Xue H, Lin B, Lu Y. A meta-analysis of interleukin-10-1082 promoter polymorphism associated with gastric cancer risk. DNA Cell Biol. 2012;31(4):582–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  239. Yu YF, Han ZG, Guo WB, Zhang GJ, Yang JK, Wu FL, et al. Interleukin-10 polymorphisms and nasopharyngeal carcinoma risk: a meta-analysis. Genet Mol Res. 2015;14(4):18945–57.

    Article  CAS  PubMed  Google Scholar 

  240. Zhang Y, Xia ZG, Zhu JH, Chen MB, Wang TM, Shen WX, et al. Association of Interleukin-10 -3575T>A and -1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis. Mol Genet Genom. 2015;290(6):2063–73.

    Article  CAS  Google Scholar 

  241. Dai ZM, Liu J, Cao XM, Zhang Y, Wang M, Liu XH, et al. Association between interleukin-10-3575T>A (rs1800890) polymorphism and cancer risk. Genet Test Mol Biomarkers. 2015;19(6):324–30.

    Article  CAS  PubMed  Google Scholar 

  242. Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. Omics. 2013;17(4):200–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Zhu Y, Wang J, He Q, Zhang JQ. The association between interleukin-10-592 polymorphism and gastric cancer risk: a meta-analysis. Med Oncol. 2011;28(1):133–6.

    Article  CAS  PubMed  Google Scholar 

  244. Li C, Tong W, Liu B, Zhang A, Li F. The −1082A>G polymorphism in promoter region of interleukin-10 and risk of digestive cancer: a meta-analysis. Sci Rep. 2014;4:5335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  245. Qi M, Liu DM, Pan LL, Lin YX. Interleukin-10 gene -592C>A polymorphism and susceptibility to gastric cancer. Genet Mol Res. 2014;13(4):8954–61.

    Article  CAS  PubMed  Google Scholar 

  246. Shao N, Xu B, Mi YY, Hua LX. IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2011;14(2):129–35.

    Article  CAS  PubMed  Google Scholar 

  247. Yu KD, Chen AX, Yang C, Fan L, Huang AJ, Shao ZM. The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk. Breast Cancer Res Treat. 2012;131(1):27–31.

    Article  CAS  PubMed  Google Scholar 

  248. Zhang S, Kong YL, Li YL, Yin YW. Interleukin-10 gene -1082 G/A polymorphism in cervical cancer and cervical intraepithelial neoplasia: meta-analysis. J Int Med Res. 2014;42(6):1193–201.

    Article  CAS  PubMed  Google Scholar 

  249. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13(16):4677–85.

    Article  PubMed  Google Scholar 

  250. Engel MA, Neurath MF. Anticancer properties of the IL-12 family--focus on colorectal cancer. Curr Med Chem. 2010;17(29):3303–8.

    Article  CAS  PubMed  Google Scholar 

  251. Zhou L, Yao F, Luan H, Wang Y, Dong X, Zhou W, et al. Functional polymorphisms in the interleukin-12 gene contribute to cancer risk: evidence from a meta-analysis of 18 case-control studies. Gene. 2012;510(1):71–7.

    Article  CAS  PubMed  Google Scholar 

  252. Chen H, Cheng S, Wang J, Cao C, Bunjhoo H, Xiong W, et al. Interleukin-12B rs3212227 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep. 2012;39(12):10235–42.

    Article  CAS  PubMed  Google Scholar 

  253. Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011;128(7):1692–6.

    Article  CAS  PubMed  Google Scholar 

  254. Yang Y, Feng R, Bi S, Xu Y. TNF-alpha polymorphisms and breast cancer. Breast Cancer Res Treat. 2011;129(2):513–9.

    Article  CAS  PubMed  Google Scholar 

  255. Pan F, Tian J, Ji CS, He YF, Han XH, Wang Y, et al. Association of TNF-alpha-308 and -238 polymorphisms with risk of cervical cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(11):5777–83.

    Article  PubMed  Google Scholar 

  256. Ding B, Fu S, Wang M, Yue C, Wang W, Zhou D, et al. Tumor necrosis factor alpha −308 G>A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecolog Cancer. 2012;22(2):213–9.

    Article  Google Scholar 

  257. Liu L, Yang X, Chen X, Kan T, Shen Y, Chen Z, et al. Association between TNF-alpha polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39(3):2683–8.

    Article  CAS  PubMed  Google Scholar 

  258. Fang F, Yao L, Yu XJ, Yu L, Wu Q, Yu L. 308 TNFalpha-G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat. 2010;122(1):267–71.

    Article  CAS  PubMed  Google Scholar 

  259. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood. 1998;91(10):3574–81.

    Article  CAS  PubMed  Google Scholar 

  260. Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis. 2007;28(1):118–23.

    Article  CAS  PubMed  Google Scholar 

  261. Seidemann K, Zimmermann M, Book M, Meyer U, Burkhardt B, Welte K, et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin’s lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(33):8414–21.

    Article  CAS  Google Scholar 

  262. Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood. 2002;100(8):3037–40.

    Article  CAS  PubMed  Google Scholar 

  263. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, et al. Polymorphism of the 5’-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998;51(6):605–12.

    Article  CAS  PubMed  Google Scholar 

  264. Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int. 2009;104(6):867–73.

    Article  CAS  PubMed  Google Scholar 

  265. Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, et al. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci. 2011;56(8):2227–36.

    Article  CAS  PubMed  Google Scholar 

  266. Pociot F, Briant L, Jongeneel CV, Molvig J, Worsaae H, Abbal M, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993;23(1):224–31.

    Article  CAS  PubMed  Google Scholar 

  267. Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991;173(1):209–19.

    Article  CAS  PubMed  Google Scholar 

  268. Zhou P, Lv GQ, Wang JZ, Li CW, Du LF, Zhang C, et al. The TNF-alpha-238 polymorphism and cancer risk: a meta-analysis. PLoS One. 2011;6(7):e22092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  269. Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, et al. Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1610–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  270. Li HH, Zhu H, Liu LS, Huang Y, Guo J, Li J, et al. Tumour necrosis factor-alpha gene polymorphism is associated with metastasis in patients with triple negative breast cancer. Sci Rep. 2015;5:10244.

    Article  PubMed  PubMed Central  Google Scholar 

  271. Jin G, Zhao Y, Sun S, Kang H. Association between the tumor necrosis factor alpha gene -308G> A polymorphism and the risk of breast cancer: a meta-analysis. Tumour Biol. 2014;35(12):12091–8.

    Article  CAS  PubMed  Google Scholar 

  272. Jin Y. Association of single nucleotide polymorphisms in tumor necrosis factor-alpha with cervical cancer susceptibility. Cell Biochem Biophys. 2015;71(1):77–84.

    Article  CAS  PubMed  Google Scholar 

  273. Xiao Q, Fu B, Chen P, Liu ZZ, Wang W, Ye Q. Three polymorphisms of tumor necrosis factor-alpha and hepatitis B virus related hepatocellular carcinoma: a meta-analysis. Medicine. 2016;95(50):e5609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  274. Guo XF, Wang J, Yu SJ, Song J, Ji MY, Cao Z, et al. TNF-alpha-308 polymorphism and risk of digestive system cancers: a meta-analysis. World J Gastroenterol. 2013;19(48):9461–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  275. Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer. 2008;98(8):1443–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  276. Yang JP, Hyun MH, Yoon JM, Park MJ, Kim D, Park S. Association between TNF-alpha-308 G/A gene polymorphism and gastric cancer risk: a systematic review and meta-analysis. Cytokine. 2014;70(2):104–14.

    Article  CAS  PubMed  Google Scholar 

  277. Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, et al. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2008;53(6):479–89.

    Article  CAS  PubMed  Google Scholar 

  278. Zhu F, Zhao H, Tian X, Meng X. Association between tumor necrosis factor-alpha rs1800629 polymorphism and risk of gastric cancer: a meta-analysis. Tumour Biol. 2014;35(3):1799–803.

    Article  CAS  PubMed  Google Scholar 

  279. Min L, Chen D, Qu L, Shou C. Tumor necrosis factor-a polymorphisms and colorectal cancer risk: a meta-analysis. PLoS One. 2014;9(1):e85187.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  280. Wang J, Jin X, Wang H, Yang J, Wang L, Lei L, et al. The -308G/A polymorphism of the tumor necrosis factor-alpha gene is associated with the risk of upper aerodigestive tract cancer: a meta-analysis. Tohoku J Exp Med. 2013;229(4):245–54.

    Article  CAS  PubMed  Google Scholar 

  281. Chen FC, Zhang F, Zhang ZJ, Meng SY, Wang Y, Xiang XR, et al. Tumor necrosis factor-alpha gene polymorphisms and risk of oral cancer: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14(12):7243–9.

    Article  PubMed  Google Scholar 

  282. Cai J, Yang MY, Hou N, Li X. Association of tumor necrosis factor-alpha 308G/A polymorphism with urogenital cancer risk: a systematic review and meta-analysis. Genet Mol Res. 2015;14(4):16102–12.

    Article  CAS  PubMed  Google Scholar 

  283. He YQ, Zhu JH, Huang SY, Cui Z, He J, Jia WH. The association between the polymorphisms of TNF-alpha and non-Hodgkin lymphoma: a meta-analysis. Tumour Biol. 2014;35(12):12509–17.

    Article  CAS  PubMed  Google Scholar 

  284. Yang C, Wang W, Zi Y, Han X, Qin X, Li J, et al. Association between tumor necrosis factor-alpha gene polymorphisms and diffuse large B-cell lymphoma in Chinese Han population: evidence from two center case-control study and a meta-analysis. Int J Clin Exp Pathol. 2015;8(10):13011–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  285. Liu N, Liu GJ, Liu J. Genetic association between TNF-alpha promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: a meta-analysis. Oncotarget. 2017;8(32):53873–85.

    PubMed  PubMed Central  Google Scholar 

  286. Xie H, Yao H, Huo Y, Li N, Cheng Y. Association between TNF-alpha gene 308G>A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2014;35(10):9693–9.

    Article  CAS  PubMed  Google Scholar 

  287. Ma L, Zhao J, Li T, He Y, Wang J, Xie L, et al. Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol. 2014;9:74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  288. Cheng K, Zhao YJ, Liu L, Wan JJ. Tumor necrosis factor-alpha 238 G/A polymorphism and risk of hepatocellular carcinoma: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3275–9.

    Article  PubMed  Google Scholar 

  289. Hui M, Yan X, Jiang Y. The tumor necrosis factor-alpha-238 polymorphism and digestive system cancer risk: a meta-analysis. Clin Exp Med. 2016;16(3):367–74.

    Article  CAS  PubMed  Google Scholar 

  290. Yu JY, Li L, Ma H, Liu K, Cheng X, Li YL, et al. Tumor necrosis factor-alpha 238 G/A polymorphism and gastric cancer risk: a meta-analysis. Tumour Biol. 2013;34(6):3859–63.

    Article  CAS  PubMed  Google Scholar 

  291. Cen G, Wu W. Association between tumor necrosis factor-alpha 857C/T polymorphism and gastric cancer: a meta-analysis. Tumour Biol. 2013;34(6):3383–8.

    Article  CAS  PubMed  Google Scholar 

  292. Wang P, Wang J, Yu M, Li Z. Tumor necrosis factor-alpha T-857C (rs1799724) polymorphism and risk of cancers: a meta-analysis. Dis Markers. 2016;2016:4580323.

    PubMed  PubMed Central  Google Scholar 

  293. Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A, et al. Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011;126(3):763–70.

    Article  CAS  PubMed  Google Scholar 

  294. Zhang Q, Zhao GS, Yuan XL, Li XH, Yang Z, Cui YF, et al. Tumor necrosis factor alpha-238G/A polymorphism and risk of breast cancer: an update by meta-analysis. Medicine. 2017;96(29):e7442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  295. Zhou P, Huang W, Chu X, Du LF, Li JP, Zhang C. The lymphotoxin-alpha 252A>G polymorphism and breast cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(5):1949–52.

    Article  PubMed  Google Scholar 

  296. Luo M, Yang Y, Luo D, Liu L, Zhang Y, Xiao F, et al. Tumor necrosis factor-alpha promoter polymorphism 308 G/A is not significantly associated with esophageal cancer risk: a meta-analysis. Oncotarget. 2016;7(48):79901–13.

    Article  PubMed  PubMed Central  Google Scholar 

  297. Yuan C, Xu XH, Xu L, Liu Y, Sun M, Ni LH, et al. No association of TNF-alpha-308G/A polymorphisms with head and neck cancer risk: a PRISMA-compliant meta-analysis. Medicine. 2017;96(25):e7298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  298. Lu PH, Tang Y, Li C, Shen W, Ji L, Guo YJ, et al. Meta-analysis of association of tumor necrosis factor alpha-308 gene promoter polymorphism with gastric cancer. Zhonghua Yu Fang Yi Xue Za Zhi [Chin J Prev Med]. 2010;44(3):209–14.

    CAS  Google Scholar 

  299. Qin H, Liu B, Shi T, Liu Y, Sun Y, Ma Y. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: a meta-analysis. J Int Med Res. 2010;38(3):760–8.

    Article  CAS  PubMed  Google Scholar 

  300. Guo YM, Wei WY, Shen XZ. Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Hepato-Gastroenterology. 2010;57(101):926–31.

    CAS  PubMed  Google Scholar 

  301. Yang Z, Lv Y, Lv Y, Wang Y. Meta-analysis shows strong positive association of the TNF-alpha gene with tumor stage in bladder cancer. Urol Int. 2012;89(3):337–41.

    Article  CAS  PubMed  Google Scholar 

  302. Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang WY, Yu K, et al. TNF polymorphisms and prostate cancer risk. Prostate. 2008;68(4):400–7.

    Article  CAS  PubMed  Google Scholar 

  303. Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de Sanjose S, Hughes AM, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010;171(3):267–76.

    Article  PubMed  PubMed Central  Google Scholar 

  304. Gong LL, Han FF, Lv YL, Liu H, Wan ZR, Zhang W, et al. TNF-alpha and LT-alpha polymorphisms and the risk of leukemia: a meta-analysis. Tumori. 2017;103(1):53–9.

    Article  CAS  PubMed  Google Scholar 

  305. Zhai K, Ding J, Zhou Y. Different role of tumor necrosis factor-alpha polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis. Int J Mol Sci. 2014;15(5):7684–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  306. Yang L, Feng R, Liu G, Liao M, Zhang L, Wang W. TNF-beta +252 A>G polymorphism and susceptibility to cancer. J Cancer Res Clin Oncol. 2013;139(5):765–72.

    Article  CAS  PubMed  Google Scholar 

  307. Xu Z, Shi R, Zhang R, Zhang D, Wang L. Association between tumor necrosis factor beta 252 A/G polymorphism and risk of gastric cancer: a meta-analysis. Tumour Biol. 2013;34(6):4001–5.

    Article  CAS  PubMed  Google Scholar 

  308. Lu R, Dou X, Gao X, Zhang J, Ni J, Guo L. A functional polymorphism of lymphotoxin-alpha (LTA) gene rs909253 is associated with gastric cancer risk in an Asian population. Cancer Epidemiol. 2012;36(6):e380–6.

    Article  CAS  PubMed  Google Scholar 

  309. Mi YY, Yu QQ, Xu B, Zhang LF, Min ZC, Hua LX, et al. Interferon gamma +874 T/A polymorphism contributes to cancer susceptibility: a meta-analysis based on 17 case-control studies. Mol Biol Rep. 2011;38(7):4461–7.

    Article  CAS  PubMed  Google Scholar 

  310. Sun Y, Lu Y, Pen Q, Li T, Xie L, Deng Y, et al. Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis. Tumour Biol. 2015;36(6):4555–64.

    Article  CAS  PubMed  Google Scholar 

  311. Zhou H, Wang L, Li X, Song J, Jiang T, Wu X, et al. Interferon-gamma +874A/T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Med Sci Monit. 2015;21:689–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  312. Ge YZ, Wang YD, Xu Z, Xu LW, Wang YP, Gu MH, et al. Lack of association between interferon gamma +874 T/A polymorphism and cancer risk: an updated meta-analysis. Tumour Biol. 2014;35(7):6405–14.

    Article  CAS  PubMed  Google Scholar 

  313. Wu Z, Sun Y, Zhu S, Tang S, Liu C, Qin W. Association of Interferon gamma +874T/A polymorphism and leukemia risk: a meta-analysis. Medicine (Baltimore). 2016;95(12):e3129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  314. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010;21(1):49–59.

    Article  CAS  PubMed  Google Scholar 

  315. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010;19(1):77–91.

    Article  CAS  PubMed  Google Scholar 

  316. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435–57.

    Article  CAS  PubMed  Google Scholar 

  317. Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE. T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2004;13(3):412–5.

    PubMed  Google Scholar 

  318. Gu D, Zhuang L, Huang H, Cao P, Wang D, Tang J, et al. TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls. Breast Cancer Res Treat. 2010;123(3):857–61.

    Article  CAS  PubMed  Google Scholar 

  319. Wei BB, Xi B, Wang R, Bai JM, Chang JK, Zhang YY, et al. TGFbeta1 T29C polymorphism and cancer risk: a meta-analysis based on 40 case-control studies. Cancer Genet Cytogenet. 2010;196(1):68–75.

    Article  CAS  PubMed  Google Scholar 

  320. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, et al. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res. 2005;65(8):3454–61.

    Article  CAS  PubMed  Google Scholar 

  321. Qi X, Zhang F, Yang X, Fan L, Zhang Y, Chen L, et al. Transforming growth factor-beta1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case-control studies. Breast Cancer Res Treat. 2010;122(1):273–9.

    Article  CAS  PubMed  Google Scholar 

  322. Cai Q, Tang Y, Zhang M, Shang Z, Li G, Tian J, et al. TGFbeta1 Leu10Pro polymorphism contributes to the development of prostate cancer: evidence from a meta-analysis. Tumour Biol. 2014;35(1):667–73.

    Article  CAS  PubMed  Google Scholar 

  323. Fan H, Yu H, Deng H, Chen X. Transforming growth factor-beta1 rs1800470 polymorphism is associated with lung cancer risk: a meta-analysis. Med Sci Monit. 2014;20:2358–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  324. Chang WW, Zhang L, Su H, Yao YS. An updated meta-analysis of transforming growth factor-beta1 gene: three polymorphisms with gastric cancer. Tumour Biol. 2014;35(4):2837–44.

    Article  CAS  PubMed  Google Scholar 

  325. Fang F, Yu L, Zhong Y, Yao L. TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis. Med Oncol. 2010;27(4):1324–8.

    Article  CAS  PubMed  Google Scholar 

  326. Wang Y, Yang H, Li L, Xia X. An updated meta-analysis on the association of TGF-beta1 gene promoter -509C/T polymorphism with colorectal cancer risk. Cytokine. 2013;61(1):181–7.

    Article  CAS  PubMed  Google Scholar 

  327. Ma X, Chen C, Xiong H, Li Y. Transforming growth factorbeta1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat. 2010;124(2):453–7.

    Article  CAS  PubMed  Google Scholar 

  328. Alqumber MA, Dar SA, Haque S, Wahid M, Singh R, Akhter N. No association of the TGF-beta1 29T/C polymorphism with breast cancer risk in Caucasian and Asian populations: evidence from a meta-analysis involving 55,841 subjects. Asian Pac J Cancer Prev. 2014;15(20):8725–34.

    Article  PubMed  Google Scholar 

  329. Huang Y, Li B, Qian J, Xie J, Yu L. TGF-beta1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25,996 subjects. Breast Cancer Res Treat. 2010;123(3):863–8.

    Article  CAS  PubMed  Google Scholar 

  330. Woo SU, Park KH, Woo OH, Yang DS, Kim AR, Lee ES, et al. Association of a TGF-beta1 gene −509 C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;124(2):481–5.

    Article  CAS  PubMed  Google Scholar 

  331. Niu W, Qi Y, Gao P, Zhu D. Association of TGFB1 -509 C>T polymorphism with breast cancer: evidence from a meta-analysis involving 23,579 subjects. Breast Cancer Res Treat. 2010;124(1):243–9.

    Article  CAS  PubMed  Google Scholar 

  332. Wang Y, Chu X, Meng X, Zou F. Association of TGF-beta1-509C/T polymorphisms with breast cancer risk: evidence from an updated meta-analysis. Tumour Biol. 2014;35(2):935–42.

    Article  CAS  PubMed  Google Scholar 

  333. Deng Z, Yang Y, Huang X, Kuang Y, Qin Z, Wang B, et al. Polymorphisms of TGFbeta1T+869C and C-509T with lung cancer risk: a meta-analysis. Adv Clin Exp Med. 2016;25(6):1165–72.

    Article  PubMed  Google Scholar 

  334. Liu Y, Lin XF, Lin CJ, Jin SS, Wu JM. Transforming growth factor beta-1 C-509T polymorphism and cancer risk: a meta-analysis of 55 case-control studies. Asian Pac J Cancer Prev. 2012;13(9):4683–8.

    Article  PubMed  Google Scholar 

  335. Zhang JM, Cui XJ, Xia YQ, Guo S. Correlation between TGF-beta1-509 C>T polymorphism and risk of digestive tract cancer in a meta-analysis for 21,196 participants. Gene. 2012;505(1):66–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Border of Immune Tolerance Education and Research Network (BITERN), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Armin Hirbod-Mobarakeh

  2. International Hematology/Oncology of Pediatrics Experts (IHOPE), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Mahsima Shabani

  3. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Mahsa Keshavarz-Fathi

  4. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Mahsa Keshavarz-Fathi

  5. Interactive Research Education and Training Association (IRETA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Farnaz Delavari

  6. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Ali Akbar Amirzargar, Behrouz Nikbin & Nima Rezaei

  7. Department of Epidemiology, Kemerovo State Medical Academy, Kemerovo, Russian Federation

    Anton Kutikhin

  8. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  9. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Nima Rezaei

Authors
  1. Armin Hirbod-Mobarakeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahsima Shabani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahsa Keshavarz-Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farnaz Delavari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ali Akbar Amirzargar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Behrouz Nikbin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anton Kutikhin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nima Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nima Rezaei .

Editor information

Editors and Affiliations

  1. Research Center for Immunodeficiencies, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hirbod-Mobarakeh, A. et al. (2020). Immunogenetics of Cancer. In: Rezaei, N. (eds) Cancer Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-30845-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-30845-2_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-30844-5

  • Online ISBN: 978-3-030-30845-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation